Lilly Rises on FDA Approval of Weight-Loss Drug Zepbound for Sleep Apnea | Global News Avenue

Eli Lilly and Company (Li Lai) Zepbound received U.S. Food and Drug Administration (FDA) The drug has been approved to treat obstructive sleep apnea in obese adults, the drugmaker announced late Friday.

after approval multiple trials Earlier this year, research showed that a tezepatide-based drug was five times more effective than a placebo Reduce respiratory interruptions Caused by obstructive sleep apnea (OSA), it is completely preventable in 50% of cases.

Zepbound is five times more effective at reducing respiratory disturbances

Eli Lilly and Company said its final trial evaluated sleep apnea and weight loss in patients taking Zepbound, some of whom used a traditional “positive airway pressure” (PAP) mask while sleeping and others who did not use a mask. The company said Zepbound was about five times more effective than a placebo at reducing the number of breathing interruptions per hour for people who didn’t use a sleep apnea mask.

“Zepbound is the first medicine to significantly improve moderate to severe OSA and support long-term weight loss in obese adults,” said Patrik Jonsson, president of Eli Lilly and Company USA.

Experiments have found that adults Zepp Bond Adults treated alone lost an average of 45 pounds, or 18 percent of their body weight, while adults treated with Zepbound plus PAP lost an average of 50 pounds, or 20 percent of their body weight.

“Nearly half of the clinical trial patients saw such an improvement that they no longer experienced OSA-related symptoms, marking a key step forward in reducing the burden of this disease and its interconnected health challenges,” Jonsson said. step.”

Zepbound receives FDA approval to treat obesity and weight loss November 2023joining another tezepatide-based drug from Eli Lilly and Company, Mounjaro. Both drugs, as well as Novo Nordisk’s (non-governmental organization) Ozempic and Wegovyhave captured most of Weight loss market booming has grown significantly in recent years.

Eli Lilly’s shares were up 1.6% at midday Monday, and are up about 34% for the year. ResMed Stock (RMD), a medical device company that generates most of its revenue from sales of sleep apnea masks, saw its shares fall 4% on Monday. be negatively affected Zepbound has been tested for sleep apnea before.